Results 1 to 10 of about 112,514 (282)

Roles of osteoprotegerin in endocrine and metabolic disorders through receptor activator of nuclear factor kappa-B ligand/receptor activator of nuclear factor kappa-B signaling [PDF]

Frontiers in Cell and Developmental Biology, 2022
Endocrine and metabolic diseases show increasing incidence and high treatment costs worldwide. Due to the complexity of their etiology and mechanism, therapeutic strategies are still lacking.
Luodan Zhang, Fa Zeng, Minmin Jiang, Minmin Jiang, Maozhen Han, Binbin Huang   +5 more
doaj   +6 more sources

Receptor activator of nuclear factor kappa B (RANK) as a determinant of peri-implantitis [PDF]

Vojnosanitetski Pregled, 2013
Background/Aim. Peri-implantitis presents inflammatory process that affects soft and hard supporting tissues of osseointegrated implant based on inflammatory osteoclastogenesis.
Rakić Mia, Nikolić-Jakoba Nataša, Struillou Xavier, Petković-Ćurčin Aleksandra, Stamatović Novak, Matić Smiljka, Janković Saša, Aleksić Zoran, Vasilić Đurđa, Leković Vojislav, Vojvodić Danilo   +10 more
doaj   +7 more sources

Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease. [PDF]

World J Gastroenterol, 2018
Concomitantly with the increase in the prevalences of overweight/obesity, nonalcoholic fatty liver disease (NAFLD) has worldwide become the main cause of chronic liver disease in both adults and children. Patients with fatty liver display features of metabolic syndrome (MetS), like insulin resistance (IR), glucose intolerance, hypertension and ...
Pacifico L, Andreoli GM, D'Avanzo M, De Mitri D, Pierimarchi P.   +4 more
europepmc   +6 more sources

Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats. [PDF]

Exp Biol Med (Maywood), 2016
The present study aims to study the role of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin (RANKL/RANK/OPG) system in cardiac hypertrophy in a spontaneous hypertension rat (SHR) model and the effects of amlodipine and atorvastatin intervention.
Lu J, Liu F, Liu D, Du H, Hao J, Yang X, Cui W.   +6 more
europepmc   +6 more sources

Immunomodulatory effects of curcumin on receptor activator of nuclear factor-kappa B ligand in periodontitis [PDF]

Mediterranean Journal of Pharmacy and Pharmaceutical Sciences
Periodontitis is a chronic inflammatory disease of the tooth-supporting structures, often causing alveolar bone loss due to increased osteoclast activity mediated by receptor activator of nuclear factor-kappa B ligand.
Fiki Muhammad Ridho
doaj   +4 more sources

Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review. [PDF]

Med Oral Patol Oral Cir Bucal, 2016
Denosumab, an anti-resorptive agent, IgG2 monoclonal antibody for human Receptor activator of nuclear factor-kappa B ligand (RANKL), has been related to the occurrence of osteonecrosis of the jaws. Thus, the aim of this study was to review the literature from clinical case reports, regarding the type of patient and the therapeutic approach used for ...
de Oliveira CC, Brizeno LA, de Sousa FB, Mota MR, Alves AP.   +4 more
europepmc   +6 more sources

Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease. [PDF]

Curr Obes Rep, 2023
Abstract Purpose of Review To summarize evidence on the potential involvement of the osteoprotegerin (OPG)/receptor activator of nuclear factor-kappa B (NF-κΒ) ligand (RANKL)/receptor activator of NF-κΒ (RANK) axis in the pathogenesis of metabolic diseases.
Vachliotis ID, Polyzos SA.
europepmc   +3 more sources

The regulation of bone turnover in ameloblastoma using an organotypic in vitro co-culture model [PDF]

Journal of Tissue Engineering, 2016
Ameloblastoma is a rare, odontogenic neoplasm with benign histopathology, but extensive, local infiltrative capacity through the bone tissue it originates in. While the mechanisms of ameloblastoma invasion through the bone and bone absorption are largely
Tuula M Eriksson, Richard M Day, Stefano Fedele, Vehid M Salih   +3 more
doaj   +4 more sources

Receptor activator of nuclear factor-kappa B is enriched in CD9-positive extracellular vesicles released by osteoclasts. [PDF]

Extracell Vesicles Circ Nucl Acids, 2023
Aim: Receptor activator of nuclear factor-kappa B (RANK)-containing extracellular vesicles (EVs) bind RANK-Ligand (RANKL) on osteoblasts, and thereby simultaneously inhibit bone resorption and promote bone formation. Because of this, they are attractive candidates for therapeutic bone anabolic agents.
Ruan S, Rody WJ, Patel SS, Hammadi LI, Martin ML, de Faria LP, Daaboul G, Anderson LS, He M, Holliday LS.   +9 more
europepmc   +3 more sources

Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study [PDF]

Medicina, 2022
The RANKL-GLYC study aims to explore the impact of the rapid correction of chronic hyperglycemia on the receptor activator of nuclear factor-kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG). RANKL and OPG are considered the main factors in
Dured Dardari, Claire Thomas, Francois-Xavier Laborne, Caroline Tourte, Elodie Henry, Megane Erblang, Stéphanie Bourdon, Alfred Penfornis, Philippe Lopes   +8 more
doaj   +2 more sources